alexa Assessment of Inflammation and Damage in Rheumatoid Art
ISSN: 2161-1165

Epidemiology: Open Access
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Assessment of Inflammation and Damage in Rheumatoid Arthritis Patients with Methotrexate Inadequate Response Receiving Tocilizumab Using Low Field MRI

Samira Rostom1*, Bouchra Amine1, Rachid Bahiri1, Fadoua Allali1, Redouane Abouqal2 and Najia Hajjaj-Hassouni1

1University Med V Souissi, Faculty of Medicine and Pharmacy, El Ayachi University Hospital, Department of Rheumatology, Rabat-Sale, Morocco

2University Med V-Souissi, Faculty of Medicine and Pharmacy, Laboratory of Biostatistical, Clinical and Epidemiological Research (LBRCE), Rabat, Morocco

Corresponding Author:
Samira Rostom
Department of Rheumatology
El Ayachi University Hospital
Sale. Morocco
Tel: 00-212-537-78-29-19/17-14
Fax: 00212537782653
E-mail: [email protected]

Received Date: April 28, 2014; Accepted Date: September 23, 2014; Published Date: September 30, 2014

Citation: Rostom S, Amine B, Bahiri R, Allali F, Abouqa R, et al. (2014) Assessment of Inflammation and Damage in Rheumatoid Arthritis Patients with Methotrexate Inadequate Response Receiving Tocilizumab Using Low Field MRI. Epidemiology (Sunnyvale) 4:173. doi: 10.4172/2161-1165.1000173

Copyright: © 2014 Rostom S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Objectives: The aim of the study was to monitor joint inflammation and destruction in rheumatoid arthritis (RA) patients receiving tocilizumab therapy using MRI and compare MRI findings with clinical, biological and radiographic data.

Methods: Inclusion criteria were patients aged between 18 and 65 years, fulfilling American College of Rheumatology 1987 criteria for RA. All patients had methotrexate inadequate response with no prior biologic exposure. All patients were evaluated clinically including disease activity score 28 (DAS28) and by low field dedicated MRI (dominant hand and wrist) at initiation of treatment with anti-IL 6 receptor antibody agents and after 6 months. The MRI images were scored using the Outcome Measures in Rheumatology Clinical Trials RAMRI score (OMERACT RAMRIS).

Results: Among 22 patients with RA included in the study; 19 were female. The mean age was 42years ±13.7. Tree patients were excluded from the study before 24 weeks because of serious side effects. The study population exhibited significant decreases in all measures of disease activity at 24 weeks. At 24 weeks, the median RAMRIS synovitis (p<0.0001) and bone edema (p=0.04) scores were significantly reduced while RAMRIS bone erosion score was unchanged. The baseline RAMRIS synovitis score was strongly correlated with delta RAMRIS edema at 24 weeks (r= - 0.46; p=0.04).

Conclusion: This study suggests a significant reduction in MRI pre-erosive lesions (synovitis and osteitis) using Tocilizumab in patients with RA with inadequate response to DMARDS. Prospective studies with long term follow-up and imaging as an outcome measure are needed.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords